Irritable Bowel Syndrome Clinical Trial
— IBSOfficial title:
Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome
Verified date | March 2024 |
Source | Thomas Jefferson University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Although underutilized, what is emerging as one of the best ways of evaluating inflammation in the body, particularly in difficult to observe regions, is through the use of Fluorodeoxyglucose (FDG) positron emission tomography (PET). FDG is taken up in the body much like glucose and is particularly taken up in areas of inflammation where there is increased metabolism. Therefore, this technology can be used to assess inflammation, and measure the reduction in inflammation as the result of integrative interventions that target dietary modifications designed to reduce inflammation. With this proposed study, we plan to use FDG PET-MRI technology to develop a more specific and sensitive approach for evaluating areas of inflammation associated with IBS and measuring improvements in that inflammation in response to effective integrative interventions.
Status | Active, not recruiting |
Enrollment | 50 |
Est. completion date | June 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria for IBS Subjects: 1. Age greater than 18 years old. 2. Meets the Rome III criteria for IBS: Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months associated with 2 or more of the following: 1) Improvement with defecation; 2) Onset associated with a change in frequency of stool; 3) Onset associated with a change in form (appearance) of stool. 3. Patients have no other pre-existing and active significant gastrointestinal medical, neurological, or psychological disorders as per review by the PI 4. Minor, stable health problems that should have no substantial effect on cerebral blood flow will be allowed (i.e. controlled hypertension, medication controlled diabetes) as per review by the PI. 5. Patients will be allowed to be taking medications or supplements at the initial intake, but they must be on a stable dose regimen for at least 1 month. 6. Able to give informed consent and willing to complete the study. Inclusion criteria for Healthy Controls: 1. No significant current active medical conditions. 2. Stable medical conditions as determined by the PI are allowed. 3. No brain or body abnormalities that would affect the acquisition or analysis of the scan. Exclusion Criteria for IBS Subjects and Healthy Controls: 1. Previous abdominal (bowel) surgery. 2. Not continuously taking antioxidants or anti-inflammatory medications ( to be reviewed by the PI. 3. No other active medical conditions potentially requiring changes in treatment regimen during the study duration. 4. Not pregnant or breast feeding 5. Enrollment in active clinical trial/ experimental therapy within the prior 30 days. 6. Subject is unable or unwilling to lie still in the scanner (i.e. due to claustrophobia or weight > 350 pounds) 7. Subject has metal in their body or other reason that they cannot undergo magnetic resonance imaging. |
Country | Name | City | State |
---|---|---|---|
United States | Thomas Jefferson University, Marcus Institute of Integrative Health Centers | Philadelphia | Pennsylvania |
United States | Thomas Jefferson University, Marcus Institute of Integrative Health Centers | Villanova | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Thomas Jefferson University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Beck Depression Inventory. | This assessment questionnaire will be used as one of the evaluation questionnaires for the study. | Baseline and 2 months | |
Other | Standard Form (SF) 36 | This 36 item assessment questionnaire will be used as one of the evaluation questionnaires for the study. | Baseline and 2 months | |
Other | Profile of Mood Scale | The Profile of Mood States (POMS) is a questionnaire of 65 single word items that asks "How have you been feeling in the past week including today." The subjects will select their response to each word that describes a mood or feeling on a Lickert scale from 1= Not at All, 2= A Little, 3=Moderately, 4=Quite a lot, to 5=Extremely. The responses are scored to generate values for Tension, Anger, Confusion, Depression and Vigor. The higher scores indicate a greater presence of that mood or state. | Baseline and 2 months | |
Other | Self-Evaluation Questionnaire | This assessment questionnaire will be used as one of the evaluation questionnaires for the study. | Baseline and 2 months | |
Other | Symptom Diary | This assessment questionnaire will be used as one of the evaluation questionnaires for the study. | Baseline and 2 months | |
Primary | Combined PET/MRI to define IBS activity and inflammation pattern. | To use PET-MRI to define abnormal brain and body activity and evaluate changes in inflammation for IBS patients. | Baseline and 2 months | |
Secondary | Use combined PET/MRI to demonstrate brain and body activity in responders and non-responders. | Patterns will be compared between those who respond and those who do not respond to dietary/nutritional program. | Baseline and 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |